Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)

Peer Review reports

Original Submission
15 Feb 2022	Submitted	Original manuscript
30 May 2022	Author responded	Author comments - Alix Schwarz
Resubmission - Version 2
30 May 2022	Submitted	Manuscript version 2
3 Sep 2022	Author responded	Author comments - Alix Schwarz
Resubmission - Version 3
3 Sep 2022	Submitted	Manuscript version 3
24 Oct 2022	Author responded	Author comments - Alix Schwarz
Resubmission - Version 4
24 Oct 2022	Submitted	Manuscript version 4
23 Jan 2023	Reviewed	Reviewer Report
9 Feb 2023	Reviewed	Reviewer Report
15 Feb 2023	Reviewed	Reviewer Report
16 Mar 2023	Author responded	Author comments - Alix Schwarz
Resubmission - Version 5
16 Mar 2023	Submitted	Manuscript version 5
22 Mar 2023	Reviewed	Reviewer Report
27 Mar 2023	Reviewed	Reviewer Report
2 Apr 2023	Reviewed	Reviewer Report
20 Apr 2023	Author responded	Author comments - Alix Schwarz
Resubmission - Version 6
20 Apr 2023	Submitted	Manuscript version 6
19 May 2023	Author responded	Author comments - Alix Schwarz
Resubmission - Version 7
19 May 2023	Submitted	Manuscript version 7
Publishing
23 May 2023	Editorially accepted
19 Jun 2023	Article published	10.1186/s12885-023-11004-z

Back to article page